

Quick reference guide

Infliximab for acute exacerbations of ulcerative colitis

Guidance

This guidance relates only to the use of infliximab within its marketing authorisation, for the treatment of acute exacerbations of severely active ulcerative colitis. It relates to an induction course of three doses of infliximab.

- 1 Infliximab is recommended as an option for the treatment of acute exacerbations of severely active ulcerative colitis only in patients in whom ciclosporin is contraindicated or clinically inappropriate, based on a careful assessment of the risks and benefits of treatment in the individual patient.
- 2 In people who do not meet the criterion in 1, infliximab should only be used for the treatment of acute exacerbations of severely active ulcerative colitis in clinical trials.

Implementation tools

NICE has developed tools to help organisations implement this guidance (listed below). These are available on our website (www.nice.org.uk/TA163).

- A costing statement explaining the resource impact of this guidance.
- Audit support for monitoring local practice.

Further information

Ordering information

You can download the following documents from www.nice.org.uk/TA163

- A quick reference guide (this document) – a summary of recommendations for healthcare professionals.
- ‘Understanding NICE guidance’ – information for patients and carers.
- The full guidance.
- Details of all the evidence that was looked at and other background information.

For printed copies of the quick reference guide or ‘Understanding NICE guidance’, phone NICE publications on 0845 003 7783 or email publications@nice.org.uk and quote:

- N1753 (quick reference guide)
- N1754 (‘Understanding NICE guidance’).

Related NICE guidance


For information about NICE guidance that has been issued or is in development, see the website (www.nice.org.uk).

Published

- Infliximab for subacute manifestations of ulcerative colitis. NICE technology appraisal guidance 140 (2008). Available from www.nice.org.uk/TA140

Updating the appraisal

This technology appraisal will be considered for review in December 2011. Information about the progress of a review will be posted on the NICE website (www.nice.org.uk/TA163).



This guidance represents the view of NICE, which was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of healthcare professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

© National Institute for Health and Clinical Excellence, 2008. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.